Skip to main navigation

About Us
Our Products
Investor Relations
News
Cumberland Emerging Technologies
Blog

About Us
Our Products
Investor Relations
News
Cumberland Emerging Technologies
Blog

Press Releases

Year

Cumberland Pharmaceuticals Announces Product Approval in Mexico

Oct 01, 2025

PDF Version

Tabuk Launches Vibativ® FDA-approved Antibiotic with Life-Saving Potential in Saudi Arabia

Sep 29, 2025

PDF Version

Cumberland Pharmaceuticals Reports 23% Revenue Growth Year-to-Date

Aug 05, 2025

Cumberland Pharmaceuticals Reports 23% Revenue Growth Year-to-Date

Cumberland Pharmaceuticals Receives Vizient Contract For New Vibativ® 4-Vial Starter Pak

Aug 04, 2025

CUMBERLANDPHARMACEUTICALS RECEIVES VIZIENT CONTRACT FOR NEW VIBATIV® 4-VIAL STARTER PAK

Cumberland Pharmaceuticals To Announce Q2 2025 Financial Results & Company Update

Jul 29, 2025

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q2 2025 FINANCIAL RESULTS & COMPANY UPDATE

Cumberland Pharmaceuticals Shares Phase 2 FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference

Jun 23, 2025

PDF Version

New Study Finds Caldolor® Safe And Effective For Opioid-Sparing Pain Management In Older Adults

May 27, 2025

PDF Version

Cumberland Pharmaceuticals Partners With Qureight To Advance Innovative Idiopathic Pulmonary Fibrosis Treatment Research

May 13, 2025

PDF Version

Cumberland Pharmaceuticals Reports 38% Revenue Growth in Q1 2025

May 06, 2025

PDF Version

Cumberland Pharmaceuticals To Announce Q1 2025 Financial Results & Company Update

Apr 29, 2025

PDF Version

First page
Previous page
Page 1
Current page 2

Displaying 11 - 20 of 20

© 2026 Cumberland Pharmaceuticals, Inc. All Rights Reserved.

Privacy Policy

Accessibility Statement

Terms of Use